Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women

Jyoti S Mathad, Rada Savic, Paula Britto, Priya Jayachandran, Lubbe Wiesner, Grace Montepiedra, Jennifer Norman, Nan Zhang, Ellen Townley, Nahida Chakhtoura, Sarah Bradford, Sandesh Patil, Stephanie Popson, Tsungai Chipato, Vanessa Rouzier, Deborah Langat, Amphan Chalermchockcharoentkit, Portia Kamthunzi, Amita Gupta, Kelly E Dooley, Jyoti S Mathad, Rada Savic, Paula Britto, Priya Jayachandran, Lubbe Wiesner, Grace Montepiedra, Jennifer Norman, Nan Zhang, Ellen Townley, Nahida Chakhtoura, Sarah Bradford, Sandesh Patil, Stephanie Popson, Tsungai Chipato, Vanessa Rouzier, Deborah Langat, Amphan Chalermchockcharoentkit, Portia Kamthunzi, Amita Gupta, Kelly E Dooley

Abstract

Background: Pregnancy increases the risk of tuberculosis and its complications. A 3-month regimen of weekly isoniazid and rifapentine (3HP) is safe and effective for tuberculosis prevention in adults and children, including those with HIV, but 3HP has not been evaluated in pregnancy.

Methods: IMPAACT 2001 was a phase I/II trial evaluating the pharmacokinetics and safety of 3HP among pregnant women with indications for tuberculosis preventative therapy in Haiti, Kenya, Malawi, Thailand, and Zimbabwe (NCT02651259). Isoniazid and rifapentine were provided at standard doses (900 mg/week). Pharmacokinetic sampling was performed with the first (second/third trimester) and twelfth (third trimester/postpartum) doses. Nonlinear mixed-effects models were used to estimate drug population pharmacokinetics.

Results: Of 50 participants, 20 had HIV and were taking efavirenz-based antiretroviral therapy. Among women without HIV, clearance of rifapentine was 28% lower during pregnancy than postpartum (1.20 vs 1.53 L/hour, P < .001), with area under the concentration-time curve (AUCSS) of 786 and 673 mg × hour/L, respectively. In pregnant women with HIV, clearance was 30% higher than women without HIV (P < .001), resulting in lower AUCss (522 mg × hour/L); clearance did not change significantly between pregnancy and postpartum. Pregnancy did not impact isoniazid pharmacokinetics. There were no drug-related serious adverse events, treatment discontinuations, or tuberculosis cases in women or infants.

Conclusions: 3HP does not require dose adjustment in pregnancy. Rifapentine clearance is higher among women with HIV, but all women achieved exposures of rifapentine and isoniazid associated with successful tuberculosis prevention. The data support proceeding with larger safety-focused studies of 3HP in pregnancy.

Clinical trials registration: ClinicalTrials.gov, NCT02651259.

Keywords: HIV; latent tuberculosis; maternal health; pharmacokinetics; rifapentine.

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
CONSORT diagram and study schema: CONSORT flow diagram showing participant flow through the IMPAACT 2001 trial. Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; DOT, directly observed therapy; GA/gest age, gestational age; IMPAACT, International Maternal Pediatric Adolescent AIDS Clinical Trial Network; PK, pharmacokinetics; TB, tuberculosis.
Figure 2.
Figure 2.
Effect of HIV on clearance of RPT in second-trimester and third-trimester trimester. There were no differences in RPT concentration between second-trimester data (intensive PK from cohort 1; left panel) and third-trimester data (intensive PK from cohort 2, sparse PK from cohort 1; right panel). RPT clearance was 30% higher in pregnant WLHIV (blue) compared with women without HIV (pink) (P < .001). Data deemed to be below the LLOQ are displayed as open black circles as the LLOQ value (0.039 μg/mL). Abbreviations: AUCSS, steady-state area under the concentration-time curve; HIV, human immunodeficiency virus; IQR, interquartile range; LLOQ, lower limit of quantification; PK, pharmacokinetics; RPT, rifapentine; RSE, relative standard error; WLHIV, women living with HIV.
Figure 3.
Figure 3.
Effect of pregnancy and HIV on INH PK: The clearance of isoniazid was comparable between pregnant and postpartum women with HIV (orange) and without HIV (blue). The AUCSS for the entire population was 78.2 mg × hour/L (IQR, 21.9–78.2) and maximum isoniazid concentration was 7.74 mg/L (IQR, 5.68–10.6). Abbreviations: AUCSS, steady-state area under the concentration-time curve; HIV, human immunodeficiency virus; IQR, interquartile range.
Figure 4.
Figure 4.
Effect of pregnancy on clearance of RPT, by HIV status: In women without HIV (left panel), the postpartum clearance (purple) was 28% higher than antepartum clearance (green). In WLHIV, the clearance of RPT antepartum and postpartum was comparable to each other, and to postpartum clearance in women without HIV. Abbreviations: HIV, human immunodeficiency virus; RPT, rifapentine; RSE, relative standard error; WLHIV, women living with HIV.

References

    1. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: A national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med 2012; 185:779–84. Available at: . Accessed 22 July 2020.
    1. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: An estimate of the global burden of disease. Lancet Glob Heal 2014; 2:e710–6. Available at: . Accessed 28 June 2021.
    1. Say L, Chou D, Gemmill A, et al. . Global causes of maternal death: A WHO systematic analysis. Lancet Glob Heal 2014; 2:e323–33.
    1. Salazar-Austin N, Hoffmann J, Cohn S, et al. . Poor obstetric and infant outcomes in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: The Tshepiso study. Clin Infect Dis 2018; 66:921–9.
    1. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: Epidemiology, management, and research gaps. Clin Infect Dis 2012; 55:1532–49.
    1. Gupta A, Bhosale R, Kinikar A, et al. . Maternal tuberculosis: A risk factor for mother-to child transmission of human immunodeficiency virus. J Infect Dis 2011; 203:358–63.
    1. Gupta A, Nayak U, Ram M, et al. . Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002–2005. Clin Infect Dis 2007; 45:241–9.
    1. Cantwell MF, Shehab ZM, Costello AM, et al. . Congenital tuberculosis. N Engl J Med 1994; 330:1051–4. Available at: . Accessed 22 July 2020.
    1. Gomes VF, Andersen A, Wejse C, et al. . Impact of tuberculosis exposure at home on mortality in children under 5 years of age in Guinea-Bissau. Thorax 2011; 66:163–7. Available at: . Accessed 3 August 2020.
    1. World Health Organization. Guidelines on the management of latent tuberculosis infection. 2015. Available at: . Accessed 10 June 2021.
    1. Kalk E, Heekes A, Mehta U, et al. . Safety and effectiveness of isoniazid preventive therapy in pregnant women living with human immunodeficiency virus on antiretroviral therapy: an observational study using linked population data. Clin Infect Dis 2020; 71:E351–8. Available at: . Accessed 7 July 2021.
    1. LaCourse S, Wagner A, Cranmer L, et al. . Brief report: high programmatic isoniazid preventive therapy (IPT) use in pregnancy among HIV-infected women. J Acquir Immune Defic Syndr 2019; 82:41–5. Available at: . Accessed 7 July 2021.
    1. Gupta A, Montepiedra G, Aaron L, et al. . Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med –; 381:1333–46.
    1. Hamada Y, Figueroa C, Martin-Sanchez M, Falzon D, Kanchar A. The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: Systematic review and meta-analysis. Eur Respir J 2020; 55. Available at: . Accessed 3 August 2020.
    1. Sterling TR, Villarino ME, Borisov AS, et al. . Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155–66.
    1. Villarino ME, Scott NA, Weis SE, et al. . Treatment for preventing tuberculosis in children and adolescents: A randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and Isoniazid. JAMA Pediatr 2015; 169:247–55. Available at: . Accessed 22 July 2020.
    1. European Medicines Agency. Guideline on bioanalytical method validation. London, UK: 2011. Available at: . Accessed 22 July 2020.
    1. Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol 2013; 2:e50.
    1. Weiner M, Savic RM, Mac Kenzie WR, et al. . Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. Orig Artic J Pediatr Infect Dis Soc 2014; 3:132–77. Available at: . Accessed 22 July 2020.
    1. Anderson GD. Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach. Clin. Pharmacokinet 2005; 44:989–008.
    1. Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin. Perinatol 2015; 39:512–9. Available at: . Accessed 3 August 2020.
    1. Abdelwahab MT, Leisegang R, Dooley KE, et al. . Population pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in pregnant South African women with tuberculosis and HIV. Antimicrob Agents Chemother 2020; 64. Available at: . Accessed 3 August 2020.
    1. Gausi K, Wiesner L, Norman J, et al. . IMPAACT P1078 (TB APPRISE) Study Group Team . Pharmacokinetics and drug-drug interactions of isoniazid and efavirenz in pregnant women living with HIV in high TB incidence settings: importance of genotyping. Clin Pharmacol Ther 2021; 109:1034–44. Available at: . Accessed 28 June 2021.
    1. Hibma JE, Radtke KK, Dorman SE, et al. . Rifapentine population pharmacokinetics and dosing recommendations for latent tuberculosis infection. Am J Respir Crit Care Med 2020. Available at: . Accessed 22 July 2020.
    1. Denti P, Martinson N, Cohn S, et al. . Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa. Antimicrob Agents Chemother 2016; 60:1234–41. Available at: . Accessed 31 July 2020.
    1. Savic RM, Lu Y, Bliven-Sizemore E, et al. . Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: Nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother 2014; 58:3035–42. Available at: . Accessed 22 July 2020.
    1. Dooley K, Flexner C, Hackman J, et al. . Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 2008; 52:4037–42. Available at: . Accessed 22 July 2020.
    1. Keung A, Eller MG, McKenzie KA, Weir SJ. Single and multiple dose pharmacokinetics of rifapentine in man: Part II. Int J Tuberc Lung Dis 1999; 3:437–44.
    1. Haas DW, Podany AT, Bao Y, et al. . Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. Pharmacogenet Genomics 2020; 31:17–27.
    1. Brooks KM, George JM, Pau AK, et al. . Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine. Clin Infect Dis 2018; 67:193–201.
    1. PMNCH | Born Too Soon: The Global Action Report on Preterm Birth. WHO; 2016; Available at: . Accessed 28 June 2021.
    1. Dolea C, Abouzahr C. Global burden of hypertensive disorders of pregnancy in the year 2000. Glob Burd Dis 2000 2003.
    1. Black RE. Global prevalence of small for gestational age births. In: Nestle Nutrition Institute Workshop Series. Basel: S. Karger AG, 2015: 1–7. Available at: . Accessed 28 June 2021.
    1. Blencowe H, Krasevec J, de Onis M, et al. . National, regional, and worldwide estimates of low birthweight in 2015, with trends from 2000: a systematic analysis. Lancet Glob Heal 2019; 7:e849–60. Available at: . Accessed 28 June 2021.
    1. Justesen US, Andersen AB, Klitgaard NA, Brosen K, Gerstoft J, Pedersen C. Pharmacokinetic Interaction between Rifampin and the Combination of Indinavir and Low-Dose Ritonavir in HIV-Infected Patients. Clin Infect Dis 2004; 38:426–9. Available at: . Accessed 28 June 2021.
    1. Moro RN, Scott NA, Vernon A, et al. . Exposure to latent tuberculosis treatment during pregnancy the PREVENT TB and the Iadhere trials. Ann Am Thorac Soc. 2018; 15:570–80. Available at: . Accessed 31 July 2020.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj